Market News How it works Learn FAQ
| RCT 0.0827 8.67% | NU 12.59 -16.95% | EWZ 34.15 -19.82% | BBD 2.93 -28.01% | TGL 0.2427 9.57% | AZTR 1.53 113.99% | ITUB 7.7 -20.37% | XP 15.705 -48.36% | NVD 3.99 -4.77% | SRTM 0.3 -30.28% | WFF 0.0898 12.25% | SPCX 146.9 -0.40% | PBR 22.5 -13.99% | SHFS 0.094 -29.00% | SOXL 90.5 8.31% | INTC 90.47 4.04% | VALE 12 -3.23% | NVDA 216 2.39% | CLRO 4.97 52.92% | NOK 8.64 6.14% | JBLU 2.37 -9.71% | TSLL 10.76 10.25% | CRWV 55.19 1.76% | GCDT 0.1545 -12.27% | SOXS 47.98 -8.54% | RIG 6.53 1.87% | NWGL 0.0869 5.98% | ABEV 2.83 -14.24% | RWM 14.5 -0.34% | BITO 10.65 -1.66% | AAL 12.2 0.74% | GPUS 0.1785 5.68% | TSLG 5.38 10.47% | T 20.85 -0.38% | SGRY 23.25 47.62% | IREN 25.43 2.11% | INTR 4.68 -34.91% | SBS 4.73 -26.09% | NFLX 63.9 -2.96% | GRAB 2.71 -2.87% | TSLA 391.62 5.21% | QID 14.22 -2.27% | WULF 11.98 5.83% | TQQQ 68.43 3.23% | CIFR 7.71 -2.90% | RBNE 0.17 -10.53% | SID 0.9118 -22.73% | SPDN 8.5 -0.47% | VZ 43.1 -3.49% | LUCD 0.5007 21.82%
ANAnthera Pharmaceuticals, Inc. logo

Anthera Pharmaceuticals, Inc. (ANTH)

Other OTC · Currency in USD
$0.00 ▼ 0.00 (-28.57%)
At close: Oct 23, 4:00 PM ET. Market closed.

Summary

Previous Close
$0.00
Open
$0.00
Day's Range
$0.00 – $0.00
52 Week Range
$0.00 – $0.00
Volume
23,894
Avg. Volume
2,259
Market Cap
$2.62K
Beta (5Y Monthly)
-5.88
PE Ratio (TTM)
--
EPS (TTM)
-$1.65
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Anthera Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
21
CEO
Paul F. Truex

Anthera Pharmaceuticals, Inc., a biopharmaceutical enterprise, concentrates on developing and commercializing therapeutic solutions for conditions with significant unmet medical needs. The company's pipeline includes Sollpura, an investigational non-porcine pancreatic enzyme replacement therapy in Phase III clinical trials for individuals with exocrine pancreatic insufficiency. It is also advancing Blisibimod, currently in Phase II clinical evaluation for B-cell mediated autoimmune diseases, such as immunoglobulin A nephropathy (IgA nephropathy).

Earnings

DateEst.Actual
May 15, 2018-$0.60-$0.57Beat
Mar 5, 2018-$0.66-$0.73Miss
Nov 6, 2017-$0.91-$0.58Beat

Analyst view

Rating: Buy
Buy 67% · Hold 25% · Sell 8%

Get free alerts on ANTH and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.